Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04458558
Other study ID # 2.1
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 30, 2020
Est. completion date April 1, 2021

Study information

Verified date July 2020
Source Center for Information and Counseling on Reproductive Health - Tanadgoma
Contact Nino Tsereteli, MA
Phone +995 599 158 030
Email tsereteli_nino@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the Republic of Georgia, the medical abortion regimen involves three in-person visits. This study aims to pilot and evaluate a simplified medical abortion service delivery model that will reduce the number of in-person visits to only one visit for diagnosis and counseling. Medication will be mailed along with two multi-level pregnancy tests to study participants, who will assess their abortion outcome at home.


Description:

This prospective cohort study of patients obtaining medical abortion medications by mail. The study investigators aim to recruit approximately 120 patients for this study across three study sites that have extensive experience providing early medical abortion. Five days after undergoing in-person consultation and necessary exams to assess eligibility for medical abortion, study team will mail study participants medical abortion pills and two multi-level urine pregnancy tests. Medical abortion follow-up will occur at the participant's home approximately two weeks after the initial visit, and the multi-level pregnancy test will be used to assess abortion outcome. At follow-up, study participants will be asked questions about the results of the multi-level pregnancy test, and their experience and feedback about the acceptability of the process. At the conclusion of the study, investigators will interview providers to better undertand their experience with the simplified medical abortion service delivery model.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date April 1, 2021
Est. primary completion date April 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Women seeking medical abortion through 58 days gestation

- Eligible for medical abortion according to study provider's assessment

- Able to receive physical mail

- Have access to a phone

- Be willing and able to consent to participate in the study

- Be willing to follow study procedures

Exclusion Criteria:

- Not seeking medical abortion

- Contraindications to medical abortion

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mifepristone
Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.

Locations

Country Name City State
Georgia Batumi Medical Center Batumi
Georgia David Gagua Clinic Tbilisi
Georgia Clinic Elite Zestap'oni

Sponsors (4)

Lead Sponsor Collaborator
Center for Information and Counseling on Reproductive Health - Tanadgoma Grand Challenges Canada, Gynuity Health Projects, Healthy Life

Country where clinical trial is conducted

Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants who report satisfactory experience Number of participants who report being "satisfied" or "very satisfied" with the simplified medical abortion service delivery model Day 14 following initial medical abortion visit
Primary Number of providers who report satisfactory experience Number of providers who report being "satisfied" or "very satisfied" with the simplified medical abortion service delivery model End of the study, month 15
Secondary Number of participants with adverse event Number of participants who had a medical problem that required them to go to the hospital, emergency department or a doctor's office (other than regularly scheduled follow-up visit) since receiving medical abortion pills Up to 6 weeks after initial medical abortion visit
Secondary Number of participants with a complete abortion with medication alone and who do not require additional interventions to complete the procedure Number of participants who report that their abortion is complete as assessed by the multi-level pregnancy test and medical history. Up to 6 weeks after initial medical abortion visit
Secondary Number of particpants with adverse event associated with mailing of medical abortion medications Number of participants who had a problem (such as delayed and lost packages) receiving medical abortion medications by mail Up to 6 weeks after initial medical abortion visit
Secondary Cost associated with the simplified medical abortion service delivery model Cost savings associated with participant travel to the clinic and cost of the standard care at the clinic. Up to 6 weeks after initial medical abortion visit
Secondary Number of participants who refuse to receive medical abortion pills by mail Number of participants who refuse to receive medical abortion pills by mail during the study period End of the study, month 15
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A